Invention Grant
- Patent Title: Mutated factor X polypeptides and uses thereof for the treatment of haemophilia
-
Application No.: US15746970Application Date: 2016-07-26
-
Publication No.: US10655119B2Publication Date: 2020-05-19
- Inventor: Olivier Christophe , Cecile Denis , Peter Lenting
- Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) , UNIVERSITE PARIS-SUD
- Applicant Address: FR Paris FR Paris
- Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE),UNIVERSITE PARIS—SUD
- Current Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE),UNIVERSITE PARIS—SUD
- Current Assignee Address: FR Paris FR Paris
- Agency: W&C IP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@5c21d519
- International Application: PCT/EP2016/067826 WO 20160726
- International Announcement: WO2017/017109 WO 20170202
- Main IPC: C12N13/00
- IPC: C12N13/00 ; C12N9/64 ; A61P7/04 ; A61K38/00
Abstract:
The present invention relates to mutated factor (FX) polypeptides and uses thereof for the treatment of haemophilia. In particular, the present invention relates to a mutated factor X (FX) polypeptide which comprises a heavy chain wherein at least one amino acid residue at position 441 and/or 448 of SEQ ID NO: 1 is mutated.
Public/Granted literature
- US20180334662A1 MUTATED FACTOR X POLYPEPTIDES AND USES THEREOF FOR THE TREATMENT OF HAEMOPHILIA Public/Granted day:2018-11-22
Information query
